| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/02/2001 | WO2001054668A1 Pharmaceutical compositions comprising a hmg reductase inhibitor |
| 08/02/2001 | WO2001054664A1 A method of administering a medicinal aerosol formulation |
| 08/02/2001 | WO2001054659A2 Slimming cosmetic composition comprising a plant extract containing a plant natriuretic peptide (pnp) |
| 08/02/2001 | WO2001054654A2 Reduction of hair growth |
| 08/02/2001 | WO2001054653A1 Galenic formulation |
| 08/02/2001 | WO2001054648A2 Treatment of disorders affecting vigilance related to myopathies |
| 08/02/2001 | WO2001054516A1 Method for inhibiting a tumor |
| 08/02/2001 | WO2001054508A1 Materials and methods for killing nematodes and nematode eggs |
| 08/02/2001 | WO2001054507A1 Methods for killing nematodes and nematode eggs using oxadiazole and oxaimidazole compounds |
| 08/02/2001 | WO2001054506A1 Methods for killing nematodes and nematode eggs using bis-amino-1,2,4-thiadiazoles |
| 08/02/2001 | WO2001054505A1 Methods for killing nematodes and nematode eggs using isoxazoline compounds |
| 08/02/2001 | WO2001054504A1 Methods for killing nematodes and nematode eggs using 1-sulphonyl piperazine-2-carboxamide derivatives |
| 08/02/2001 | WO2001054503A1 Methods for killing nematodes and nematode eggs using 4-phenoxy-6-aminopyrimidine derivatives |
| 08/02/2001 | WO2001054502A2 Concentrated solution of quaternary ammonium compounds and methods of use |
| 08/02/2001 | WO2001054499A1 Treatment for dry mouth employing carbamide peroxide |
| 08/02/2001 | WO2001054498A1 Methods using substituted hydroxyproline derivatives for killing nematodes and nematode eggs |
| 08/02/2001 | WO2001054481A2 Enhanced propertied pharmaceuticals |
| 08/02/2001 | WO2001016114A3 Heterocyclic compounds and methods for modulating cxcr3 function |
| 08/02/2001 | WO2001015547A3 Active agent preparation for veterinary use and method for the production thereof |
| 08/02/2001 | WO2001014330A3 Phenylpiperazines as serotonin reuptake inhibitors |
| 08/02/2001 | WO2001013932A3 Stimulation of sperm function |
| 08/02/2001 | WO2001012189A8 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 08/02/2001 | WO2001005389A3 N-sulfonylaminiacid derivatives as inhibitors of metalloprteinase |
| 08/02/2001 | WO2001005385A3 New use of a macrolide compound for treating neurodegenerative disorders |
| 08/02/2001 | WO2001004112A3 Benzofurane derivatives |
| 08/02/2001 | WO2001003325A3 Use of creatine and/or creatine derivatives for treating feelings of ill-health in women |
| 08/02/2001 | WO2001001969A3 Methods of treating and/or suppressing weight gain |
| 08/02/2001 | WO2001000828A3 Compositions and methods for the therapy and diagnosis of lung cancer |
| 08/02/2001 | WO2000078298A3 Programming ovulation by administering estrogen such as estradiol |
| 08/02/2001 | WO2000076971A3 Serine protease inhibitors |
| 08/02/2001 | WO2000074663A3 Use of allicin for control of weight in mammals |
| 08/02/2001 | WO2000070036A3 Genes expressed in hippocampus |
| 08/02/2001 | WO2000069887A3 Rapid dehydration of proteins |
| 08/02/2001 | WO2000067847A3 Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders |
| 08/02/2001 | WO2000067801A3 Prodrugs of chemotherapeutic agents with oxaalkanoic acids |
| 08/02/2001 | WO2000066564A8 Benzimidazolones and analogues and their use as progesterone receptor ligands |
| 08/02/2001 | WO2000066175A3 Conjugates as therapies for cancer and prostate diseases |
| 08/02/2001 | WO2000051589A9 VACUOLAR-TYPE (H+)-ATPase-INHIBITING COMPOUNDS, COMPOSITIONS, AND USES THEREOF |
| 08/02/2001 | WO2000047625A3 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith |
| 08/02/2001 | WO2000047603A3 16-hydroxyestratrienes as selective estrogens |
| 08/02/2001 | WO2000046391A9 Genes displaying enhanced expression during cellular senescence and terminal cell differentiation and uses thereof |
| 08/02/2001 | WO2000028996A9 Cosmetic or dermatological use of 7-hydroxylated steroids alone and/or in combination with elastin derived peptides |
| 08/02/2001 | WO1999066918A8 Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| 08/02/2001 | WO1999049025A3 Human vault rna |
| 08/02/2001 | US20010011161 Medical probe with stylets |
| 08/02/2001 | US20010011146 Pevention cell degradation |
| 08/02/2001 | US20010011136 Anticancer agents |
| 08/02/2001 | US20010011135 Anticancer agents |
| 08/02/2001 | US20010011134 Cyclic and heterocyclic N-substituted alpha-iminohydroxamic and -carboxylic acids |
| 08/02/2001 | US20010011127 Modulating activity of endogenous protein |
| 08/02/2001 | US20010011124 Genetic engineering |
| 08/02/2001 | US20010011104 Administering carbetapentane, phenylephrine or chlorphenitamine tannate |
| 08/02/2001 | US20010011103 Pure isomers |
| 08/02/2001 | US20010011102 Single-dose antihistamine/decongestant formulations for treating rhinitis |
| 08/02/2001 | US20010011101 Renin inhibitor |
| 08/02/2001 | US20010011100 Use of an angiogenesis inhibitor as a lead compound in drug development |
| 08/02/2001 | US20010011099 Prevent oxidative damage to organs |
| 08/02/2001 | US20010011098 Pharmaceutical composition for angiotensin II-mediated diseases |
| 08/02/2001 | US20010011097 Methods and compositions for treating and preventing mucositis |
| 08/02/2001 | US20010011095 Therapy for obsessive-complusive disorder |
| 08/02/2001 | US20010011093 Arylgycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds |
| 08/02/2001 | US20010011092 High affinity ligands for nociceptin receptor ORL-1 |
| 08/02/2001 | US20010011091 Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists |
| 08/02/2001 | US20010011090 Calciumm channel blockers; therapy for asthma, arthritis |
| 08/02/2001 | US20010011086 Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment |
| 08/02/2001 | US20010011085 4-substituted cephem derivatives as elastase inhibitors |
| 08/02/2001 | US20010011084 Use of estrogen to modify the amount of serotonin transporter or its mrna |
| 08/02/2001 | US20010011083 Pain reliever and method of use |
| 08/02/2001 | US20010011082 Mixture with chelate compound; bone disorders |
| 08/02/2001 | US20010011081 Pharmaceutical composition comprising L- carnitine or alkanoyl L-carnitine for the prevention and treatment of diseases brought about by lipid metabolism disorders |
| 08/02/2001 | US20010011080 Composition containing sucrafate and a topical anesthetic for humans and animals and method of use thereof |
| 08/02/2001 | US20010011077 Secreted cysteine rich protein-6 (SCRP-6); polynucleotides and processes for producing polypeptides |
| 08/02/2001 | US20010011074 Antiischemic agents; cardiovascular disorders |
| 08/02/2001 | US20010011070 Reduce concentration of phenylalanine in blood |
| 08/02/2001 | US20010010925 Medical diagnosis/screening, inflammation; extracellular signal molecules; antitumor and antimetastasis agents |
| 08/02/2001 | US20010010922 Degrading B-cell lymphomas in cells using phosphorylation inductors such as mitogen-activated protein kinase, antibodies, anti-immunoglobulins antibodies; treatment of (non-Hodgkin's) lymphoma |
| 08/02/2001 | US20010010920 Complex of rapamycin-42 ester with dicarboxylic acid and fluorescein; antibody detection/generation; immunoglobulins; hybridomas; ring opening; precipitation |
| 08/02/2001 | US20010010834 Reducing the lead content on the inner surface of the hollow component part by treatment with a hydracid aqueous reducing solution, chemically tinning the hollow parts, such as tube or joints or fittings made of copper alloy |
| 08/02/2001 | US20010010827 Maintaining biological sample under conditions which minimize or prevent exchange of gases between the sample and atmospheric air prior to measurement of ionized magnesium, measuring ionized concentrations, comparing with normal |
| 08/02/2001 | US20010010825 Rapidly disintegrable solid preparation |
| 08/02/2001 | US20010010822 For pharmaceutical preparations |
| 08/02/2001 | US20010010821 For treatment of gastrointestinal disorders |
| 08/02/2001 | US20010010820 Delaying onset of insulin dependent diabetes mellitus by administering immunologically active monoclonal antibody against glutamic acid decarboxylase coupled to a nonimmunogenic polymer that provides shell around antibody |
| 08/02/2001 | US20010010818 Methods and formulations for reducing circulating antibodies |
| 08/02/2001 | EP1144431A3 16-hydroxyestratrienes as selective estrogens |
| 08/02/2001 | DE10038108A1 Pharmazeutische Zusammensetzungen Pharmaceutical compositions |
| 08/02/2001 | DE10004289A1 Behandlungen von Sexualfunktionsstörungen mit Phosphodiesterase 4-Hemmern als Monotherapie oder in Kombination mit anderen Phosphodiesterase-Hemmern oder Stimulatoren der Adenylat-Zyklase Treatments of sexual dysfunction with phosphodiesterase 4 inhibitors as monotherapy or in combination with other phosphodiesterase inhibitors or stimulators of adenylate cyclase |
| 08/02/2001 | DE10004157A1 New pyridyl- or pyrimidinyl-substituted bicyclic pyrrole derivatives, are cyclokine release inhibitors useful for treating immune system-related disorders, e.g. cancer, multiple sclerosis or arthritis |
| 08/02/2001 | DE10003786A1 Galenische Formulierung Drug formulation |
| 08/02/2001 | DE10003757A1 Ibuprofen-Wirkstoffzubereitung Ibuprofen drug preparation |
| 08/02/2001 | DE10003620A1 Non-aqueous solution or suspension of 5-aminolevulinic acid, is useful in the treatment or diagnosis of tumor diseases or psoriasis by photodynamic therapy |
| 08/02/2001 | DE10003582A1 Production of a tin layer on the inner surface of hollow copper alloy parts e.g., brass comprises reducing the lead content of the inner surface by treating with an aqueous reduction solution and plating with tin |
| 08/02/2001 | CA2398821A1 Composition for treatment of stress |
| 08/02/2001 | CA2398792A1 Auxiliary medicament for ophthalmic operation |
| 08/02/2001 | CA2398728A1 Novel melanocortin receptor agonists and antagonists |
| 08/02/2001 | CA2398660A1 Human cyr61 |
| 08/02/2001 | CA2398655A1 Synthesis of water soluble 9-dihydro-paclitaxel derivatives from 9-dihydro-13-acetylbaccatin iii |
| 08/02/2001 | CA2398643A1 Novel compounds |
| 08/02/2001 | CA2398642A1 Mucin synthesis inhibitors |
| 08/02/2001 | CA2398631A1 Slimming cosmetic composition comprising as an ative agent a plant extract containing a plant natriuretic peptide (pnp) |